TKTL1 has recently been used as a biomarker in a blood test based on the epitope detection in monocytes (EDIM) technology, allowing for the non-invasive detection of neoplasia and tumor recurrence, and thereby it has been proposed as a therapeutic target [42]. This evidence concerns the gene TKTL1 and neoplasm.